CoChat

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

Open access
Ravi, P, Kumar, S, Larsen, J T, Gonsalves, W, Buadi, F, Lacy, M Q, Go, R, Dispenzieri, A, Kapoor, P, Lust, J A, Dingli, D, Lin, Y, Russell, S J, Leung, N, Gertz, M A, Kyle, R A, Bergsagel, P L, Rajkumar, S V · 2016 · Blood Cancer Journal
Cited by 77

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

We studied 190 patients with smoldering multiple myeloma (SMM) at our institution between 1973 and 2014. Evolving change in monoclonal protein level (eMP) was defined as ⩾10% increase in serum monoclonal protein (M) and/or immunoglobulin (Ig) (M/Ig) within the first 6 months of diagnosis (only if M-protein ⩾3 g/dl) and/or ⩾25% increase in M/Ig within the first 12 months, with a minimum required increase of 0.5 g/dl in M-protein and/or 500 mg/dl in Ig. Evolving change in hemoglobin (eHb) was defined as ⩾0.5 g/dl decrease within 12 months of diagnosis. A total of 134 patients (70.5%) progressed to MM over a median follow-up of 10.4 years. On multivariable analysis adjusting for factors known to predict for progression to MM, bone marrow plasma cells ⩾20% (odds ratio (OR)=3.37 (1.30–8.77), P=0.013), eMP (OR=8.20 (3.19–21.05), P<0.001) and eHb (OR=5.86 (2.12–16.21), P=0.001) were independent predictors of progression within 2 years of SMM diagnosis. A risk model comprising these variables was constructed, with median time to progression of 12.3, 5.1, 2.0 and 1.0 years among patients with 0–3 risk factors respectively. The 2-year progression risk was 81.5% in individuals who demonstrated both eMP and eHb, and 90.5% in those with all three risk factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bcj.2016.65

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 77

Metadata

Authors
Ravi, P., Kumar, S., Larsen, J. T., Gonsalves, W., Buadi, F., Lacy, M. Q., Go, R., Dispenzieri, A., Kapoor, P., Lust, J. A., Dingli, D., Lin, Y., Russell, S. J., Leung, N., Gertz, M. A., Kyle, R. A., Bergsagel, P. L., & Rajkumar, S. V.
Venue
Blood Cancer Journal
Published
2016-07-29
Volume
6
Issue
7
Pages
e454-e454
ISSN
2044-5385 (ISSN-L)
OpenAlex
W2504076934
Cited by
77
References
6
FWCI
5.27
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. https://app.cochat.ai/papers/10.1038/bcj.2016.65
The paper
Ravi, P., Kumar, S., Larsen, J. T., Gonsalves, W., Buadi, F., Lacy, M. Q., Go, R., Dispenzieri, A., Kapoor, P., Lust, J. A., Dingli, D., Lin, Y., Russell, S. J., Leung, N., Gertz, M. A., Kyle, R. A., Bergsagel, P. L., & Rajkumar, S. V. (2016). Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer Journal. https://doi.org/10.1038/bcj.2016.65

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.